🟢 LLY up 4.1% today as Eli Lilly's Jaypirca receives positive EU recommendation for CLL

Eli Lilly (LLY) is trading 4.1% up at $1,173.96 today, following a positive opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) for its drug Jaypirca (pirtobrutinib) for chronic lymphocytic leukemia (CLL).

• The recommendation covers adults with CLL across all lines of therapy, regardless of prior BTK inhibitor treatment, and is a crucial step towards market authorization in the EU.
• The stock also continues to benefit from overall strong investor sentiment towards leaders in the obesity and diabetes drug market, with recent positive data from the ADA 2026 Scientific Sessions on its GLP-1 pipeline.